Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) FCF Margin (2022 - 2025)

Historic FCF Margin for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to 286.85%.

  • Stoke Therapeutics' FCF Margin rose 1569200.0% to 286.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.47%, marking a year-over-year increase of 5313300.0%. This contributed to the annual value of 238.15% for FY2024, which is 7035700.0% up from last year.
  • Stoke Therapeutics' FCF Margin amounted to 286.85% in Q3 2025, which was up 1569200.0% from 185.11% recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' FCF Margin ranged from a high of 1055.0% in Q1 2022 and a low of 897.18% during Q2 2023
  • Moreover, its 4-year median value for FCF Margin was 443.77% (2024), whereas its average is 372.74%.
  • As far as peak fluctuations go, Stoke Therapeutics' FCF Margin crashed by -14801000bps in 2023, and later surged by 6660100bps in 2025.
  • Stoke Therapeutics' FCF Margin (Quarter) stood at 697.12% in 2022, then fell by -7bps to 745.11% in 2023, then skyrocketed by 86bps to 102.75% in 2024, then tumbled by -179bps to 286.85% in 2025.
  • Its FCF Margin was 286.85% in Q3 2025, compared to 185.11% in Q2 2025 and 83.04% in Q1 2025.